Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
BCRX similar filings
- 15 Dec 22 BioCryst Discontinues Development of BCX9930 and Shifts Focus to Potential Once-daily, Oral Factor D Inhibitor, BCX10013
- 1 Nov 22 BioCryst Reports Third Quarter 2022 Financial Results and Upcoming Key Milestones
- 14 Sep 22 BioCryst Names Dr. Bill Sheridan Chief Development Officer and Appoints Dr. Ryan Arnold Chief Medical Officer
- 25 Aug 22 Regulation FD Disclosure
- 4 Aug 22 BioCryst Reports Second Quarter 2022 Financial Results and Upcoming Key Milestones
- 7 Jun 22 Departure of Directors or Certain Officers
- 5 May 22 BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones
Filing view
External links